The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 22, 2019

Filed:

Feb. 15, 2017
Applicant:

Celldex Therapeutics, Inc., Hampton, NJ (US);

Inventors:

Yaron Hadari, Harrison, NY (US);

Elizabeth M Mandel-Bausch, Pleasant Prairie, WI (US);

Francis Joseph Carr, Balmedie, GB;

Timothy David Jones, Babraham, GB;

Laura Clare Alexandra Perry, Lidgate, GB;

Assignee:

Celldex Therapeutics, Inc., Hampton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); A61K 31/4045 (2006.01); A61K 31/506 (2006.01); A61K 38/19 (2006.01); A61K 45/06 (2006.01); G01N 33/566 (2006.01); C07K 16/32 (2006.01); G01N 33/574 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 31/4045 (2013.01); A61K 31/506 (2013.01); A61K 38/19 (2013.01); A61K 39/3955 (2013.01); A61K 39/39533 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6851 (2017.08); C07K 16/2803 (2013.01); C07K 16/32 (2013.01); C12Y 207/10001 (2013.01); G01N 33/566 (2013.01); G01N 33/5748 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70596 (2013.01); G01N 2333/91205 (2013.01);
Abstract

Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.


Find Patent Forward Citations

Loading…